发布求助
文献互助 智能选刊 最新文献

Seminars in cutaneous medicine and surgery最新文献

筛选
英文 中文
Oral small molecules for psoriasis. 口服小分子治疗牛皮癣。
Seminars in cutaneous medicine and surgery Pub Date : 2018-09-01 DOI: 10.12788/j.sder.2018.046
Sanminder Singh, April W Armstrong
{"title":"Oral small molecules for psoriasis.","authors":"Sanminder Singh,&nbsp;April W Armstrong","doi":"10.12788/j.sder.2018.046","DOIUrl":"https://doi.org/10.12788/j.sder.2018.046","url":null,"abstract":"<p><p>Psoriasis is chronic inflammatory skin condition that imposes a significant physical and psychosocial burden on patients. Moderate to severe psoriasis often requires systemic treatments, including oral systemic therapies and biologics. An addition to the treatment repository for psoriasis is oral small molecules, which include apremilast, tofacitinib, and ponesimod. Of these 3 medications, only apremilast is currently approved for the treatment of psoriasis. Long-term safety data for apremilast suggest that it has a tolerable safety profile and leads to significant improvement in patients with psoriasis; however, there are few head-to-head comparisons with other oral systemic medications. Tofacitinib and ponesimod have demonstrated clinical efficacy in treating psoriasis; however, further studies are required to understand the benefit-risk profile of these medications in psoriasis patients.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 3","pages":"163-166"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36491870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases. JAK-STAT信号通路抑制:在多种皮肤病治疗中的作用
Seminars in cutaneous medicine and surgery Pub Date : 2018-09-01 DOI: 10.12788/j.sder.2018.041
Jared Kahn, Sandhya Chowdary Deverapalli, David Rosmarin
{"title":"JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases.","authors":"Jared Kahn,&nbsp;Sandhya Chowdary Deverapalli,&nbsp;David Rosmarin","doi":"10.12788/j.sder.2018.041","DOIUrl":"https://doi.org/10.12788/j.sder.2018.041","url":null,"abstract":"<p><p>Cutaneous inflammatory conditions such as psoriasis, atopic dermatitis, alopecia areata, vitiligo, and connective tissue diseases often remain a challenge to treat. Although there is an in-depth understanding of the clinical presentation of these diseases, much less is known regarding the pathophysiology. This has limited the effective treatment options for patients. A more detailed understanding of the pathogenesis of each disease will lead to newer targeted medications with less morbidity. Though there are different pathways involved in these diseases, the Janus Kinase (JAK)-Signal Transducer and Activator of Transcription proteins (STAT) signaling pathway is common to them all. Therefore, this review article endeavors to substantiate the immunopathology and clinical utility of the JAK inhibitors as treatments for different chronic inflammatory diseases of the skin.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 3","pages":"198-208"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36491874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Ustekinumab for the treatment of psoriasis: an evidence update. 乌斯特金单抗治疗牛皮癣:最新证据
Seminars in cutaneous medicine and surgery Pub Date : 2018-09-01 DOI: 10.12788/j.sder.2018.040
Zenas Zn Yiu, Richard B Warren
{"title":"Ustekinumab for the treatment of psoriasis: an evidence update.","authors":"Zenas Zn Yiu,&nbsp;Richard B Warren","doi":"10.12788/j.sder.2018.040","DOIUrl":"https://doi.org/10.12788/j.sder.2018.040","url":null,"abstract":"<p><p>Ustekinumab is an interleukin-12/23 inhibitor used for the treatment of moderate-to-severe psoriasis. Here, we review new evidence since ustekinumab was licensed for relative efficacy in comparison with other biologic therapies from head-to-head randomized controlled trials and network meta-analyses for the treatment of psoriasis. We also review observational data emerging from psoriasis registries reporting the effectiveness and safety of ustekinumab. Overall, new evidence suggests that ustekinumab has a favorable balance between efficacy/effectiveness, safety, and tolerability and should remain a first-line biologic therapy option for patients with severe psoriasis at present.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 3","pages":"143-147"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36492428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa. 中重度化脓性汗腺炎生物治疗综述及最新进展。
Seminars in cutaneous medicine and surgery Pub Date : 2018-09-01 DOI: 10.12788/j.sder.2018.042
Martina L Porter, Nicole M Golbari, Stephen J Lockwood, Alexa B Kimball
{"title":"Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa.","authors":"Martina L Porter,&nbsp;Nicole M Golbari,&nbsp;Stephen J Lockwood,&nbsp;Alexa B Kimball","doi":"10.12788/j.sder.2018.042","DOIUrl":"https://doi.org/10.12788/j.sder.2018.042","url":null,"abstract":"<p><p>Hidradenitis suppurativa (HS) is a frequently devastating inflammatory skin disorder. Although many treatments have been tried and tested to date, there is only one Food and Drug Administration-approved treatment option, adalimumab, which is currently indicated for moderateto- severe HS. Our understanding of the management of HS with biologic agents and with nonantibiotic and/ or antimicrobial systemic therapies continues to evolve. In this article, we summarize the existing data on biologics and other small-molecule systemic agents, as well as share our personal experiences with the pharmacological management of HS in the clinical setting. Continued challenges that limit our ability to study and treat this disease effectively include a lack of a universally employed scoring system for disease severity, high variability in clinical presentation, high cost of off-label therapy, and the scarcity of long-term studies on treatment response and medication safety.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 3","pages":"182-189"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36489153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Novel therapies in the treatment of atopic dermatitis. 治疗特应性皮炎的新疗法。
Seminars in cutaneous medicine and surgery Pub Date : 2018-09-01 DOI: 10.12788/j.sder.2018.044
Connie S Zhong, Sarina B Elmariah
{"title":"Novel therapies in the treatment of atopic dermatitis.","authors":"Connie S Zhong, Sarina B Elmariah","doi":"10.12788/j.sder.2018.044","DOIUrl":"10.12788/j.sder.2018.044","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a common cutaneous condition characterized by epidermal barrier disruption, severe skin inflammation, and pruritus. As a result of our growing understanding of disease pathogenesis, the therapeutic armamentarium to manage AD is rapidly expanding. Moving beyond broadly immunosuppressive agents, newer therapies for AD offer more targeted immunomodulation in the forms of phosphodiesterase 4 inhibitors, Janus kinase inhibitors, and anticytokine monoclonal antibodies. While such therapies are generally considered safer than traditional immunosuppressive agents that have been used off label for AD for decades, they are not without risk entirely. In some cases, potential side effects may be difficult to manage. This review summarizes current views on AD pathogenesis and discusses these novel and emerging therapies, including a discussion of the mechanisms of action, potential side effects, and limitations of current clinical trials for each drug. While the rapid and prolific expansion of therapies to treat AD is encouraging, additional studies are needed to adequately evaluate the long-term safety, efficacy, and generalizability among different age groups and disease subtypes.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 3","pages":"190-197"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36491873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Targeted therapies for pediatric psoriasis. 小儿银屑病的靶向疗法。
Seminars in cutaneous medicine and surgery Pub Date : 2018-09-01 DOI: 10.12788/j.sder.2018.048
Gene Schwartz, Amy S Paller
{"title":"Targeted therapies for pediatric psoriasis.","authors":"Gene Schwartz, Amy S Paller","doi":"10.12788/j.sder.2018.048","DOIUrl":"10.12788/j.sder.2018.048","url":null,"abstract":"<p><p>Children who are recalcitrant to topical therapy for their moderate to severe plaque psoriasis and/or highly visible lesions may be candidates for systemic therapy. Methotrexate has been the most commonly used systemic agent in children. However, at least 25% of patients are now treated with biologics, especially tumor necrosis factor-α inhibitors, and their use is expanding as their availability, demonstrated safety and efficacy, and practitioner experience are increasing. In the United States, etanercept is Food and Drug Administration approved for ages 6 years and older and ustekinumab for 12 years of age and older. In Europe, adalimumab is also approved for pediatric psoriasis for 4 years of age and older. While biologics have the advantage of less frequent administration, greater and more rapid efficacy than methotrexate, fewer side effects, and a less rigorous need for monitoring, their cost is much higher than that of methotrexate and other systemic medications, concerns about the development of neutralizing antibodies necessitate continuous treatment, and their long-term safety profile remains to be determined.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 3","pages":"167-172"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36492427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Immunotherapy for melanoma. 黑色素瘤的免疫疗法。
Seminars in cutaneous medicine and surgery Pub Date : 2018-06-01 DOI: 10.12788/j.sder.2018.028
Lauren M Cuevas, Adil I Daud
{"title":"Immunotherapy for melanoma.","authors":"Lauren M Cuevas,&nbsp;Adil I Daud","doi":"10.12788/j.sder.2018.028","DOIUrl":"https://doi.org/10.12788/j.sder.2018.028","url":null,"abstract":"<p><p>Immunotherapy for the treatment of advanced melanoma has become a primary treatment in the clinic. Current therapies include systemic cytokines, immune checkpoint inhibitors, and localized intratumoral therapies. Checkpoint inhibitors block natural pathways that dampen or inhibit an immune response to stimulus. These pathways include programmed cell death 1 receptor/programmed death-ligand 1 and cytotoxic T lymphocyte antigen-4. Systemic immunotherapies have proven to be effective in clinical trials both as monotherapy and in combination therapy. Oncolytic viruses are used to treat tumor locally and induce an effective immune response. Although some immune-mediated adverse events have been shown to occur with immunotherapy and may cause disease through systemic immune activation, most symptoms are mild to moderate. Overall immunotherapy in advanced melanoma has provided effective and durable responses to treat patients with advanced melanoma.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":" ","pages":"127-131"},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36339162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
Biomarkers for immune therapy in melanoma. 黑色素瘤免疫疗法的生物标志物。
Seminars in cutaneous medicine and surgery Pub Date : 2018-06-01 DOI: 10.12788/j.sder.2018.019
Douglas B Johnson, Jeewon Chon, Mark R Johnson, Justin M Balko
{"title":"Biomarkers for immune therapy in melanoma.","authors":"Douglas B Johnson, Jeewon Chon, Mark R Johnson, Justin M Balko","doi":"10.12788/j.sder.2018.019","DOIUrl":"10.12788/j.sder.2018.019","url":null,"abstract":"<p><p>Immune checkpoint inhibitors have dramatically transformed melanoma treatment options. However, intrinsic and acquired resistance remain fundamental limitations to extending the benefits to all patients. Understanding molecular and clinical features that correlate with response to treatment (biomarkers) may unravel therapeutic resistance, assist in treatment decision-making, and facilitate drug development. An intensive effort to characterize these biomarkers is underway. Herein, we highlight promising molecular biomarkers involving the tumor microenvironment, host immune response, and microbiome. We particularly focus on anti-programmed death-1 (PD-1) therapy but will also briefly cover anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) and novel combination therapies.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 2","pages":"120-126"},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189357/pdf/nihms-1892104.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9479178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treating Acne in Patients With Skin of Color. 有色人种痤疮的治疗。
Seminars in cutaneous medicine and surgery Pub Date : 2018-06-01 DOI: 10.12788/j.sder.2018.027
Andrew F Alexis, Julie C Harper, Linda F Stein Gold, Jerry K L Tan
{"title":"Treating Acne in Patients With Skin of Color.","authors":"Andrew F Alexis,&nbsp;Julie C Harper,&nbsp;Linda F Stein Gold,&nbsp;Jerry K L Tan","doi":"10.12788/j.sder.2018.027","DOIUrl":"https://doi.org/10.12788/j.sder.2018.027","url":null,"abstract":"<p><p>Patients with skin of color are more likely to develop acne and postinflammatory hyperpigmentation (PIH). Many therapies for acne have demonstrated efficacy in darker skin types and in the treatment of PIH. Semin Cutan Med Surg 37(supp3):S71-S73 © 2018 published by Frontline Medical Communications.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 3S","pages":"S71-S73"},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36471486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Current Concepts in Acne Pathogenesis: Pathways to Inflammation. 当前痤疮发病机制的概念:炎症途径。
Seminars in cutaneous medicine and surgery Pub Date : 2018-06-01 DOI: 10.12788/j.sder.2018.024
Jerry K L Tan, Linda F Stein Gold, Andrew F Alexis, Julie C Harper
{"title":"Current Concepts in Acne Pathogenesis: Pathways to Inflammation.","authors":"Jerry K L Tan,&nbsp;Linda F Stein Gold,&nbsp;Andrew F Alexis,&nbsp;Julie C Harper","doi":"10.12788/j.sder.2018.024","DOIUrl":"https://doi.org/10.12788/j.sder.2018.024","url":null,"abstract":"<p><p>Acne is a disease of pilosebaceous inflammation. Pivotal in pathogenesis are the roles of hormones (insulin, insulin-like growth factor-1, androgens), Propionibacterium acnes, lipogenesis, and a proinflammatory lipid profile. Innate immune responses are induced through interaction with toll-like receptors and inflammasome activation initially and subsequently through adaptive immune activation. These insights into pathogenic inflammatory pathways can translate into novel therapeutic approaches for acne. Semin Cutan Med Surg 37(supp3):S60-S62 ©2018 published by Frontline Medical Communication.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 3S","pages":"S60-S62"},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36472085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 26
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信